Micron biomedical secures $43 million in total grant support to improve coverage of measles and rubella vaccine and accelerate world's first phase 2 trial of needle-free drug and vaccine technology in infants

New $7.5m grant builds on prior funding and follows positive phase 1/2 data recently published in the lancet gates foundation's david robinson joins micron biomedical's board as an observer to support the accelerated commercialization of micron's technology atlanta, jan. 07, 2025 (globe newswire) -- micron biomedical, a life science company developing the world's first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, today announced the company secured a $7.5 million grant from the bill & melinda gates foundation that brings total grant funding from the organization to $43 million. the grant will support micron's efforts in increasing access to measles-rubella (mr) vaccine and this latest tranche will fund ongoing manufacturing scale-up efforts and activities to support a phase 2 trial in infants.
MU Ratings Summary
MU Quant Ranking